Full-Time

Medical Science Liaison

Endocrinology

Confirmed live in the last 24 hours

Corcept Therapeutics

Corcept Therapeutics

201-500 employees

Develops cortisol modulators for medical conditions

Biotechnology
Healthcare

Compensation Overview

$172.3k - $253.3kAnnually

Senior, Expert

Remote in USA

Candidates must be currently authorized to work in the United States on a full-time basis.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary

You match the following Corcept Therapeutics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Clinical science degree; advanced degree in medical science is required (MD, PhD, PharmD, NP, PA)
  • 7+ years MSL experience with therapeutic area expertise highly preferred
Responsibilities
  • Engage in clinically meaningful scientific discussion with thought leaders (TLs) and HCPs to build knowledge and advocacy for Cushing’s syndrome and Corcept’s FDA approved product(s)
  • Provide scientific presentations and educational programs to HCPs regarding Corcept’s products, disease states, and clinical trials
  • Develop and maintain strong working relationships with thought leaders (TLs) and organizations within the medical community
  • Proactively or responsively support Corcept products via healthcare professional communication and education
  • Respond to medical inquiries from HCPs in a timely and scientifically accurate manner
  • Generate scientific content intended for healthcare providers
  • Attend and participate in medical conferences and other scientific events
  • Able to critically review scientific literature and provide evidenced-based insights
  • Capture, analyze, synthesize, and report insights and intelligence from the medical and scientific community in a compliant manner in order to help inform decisions by Corcept
  • Support clinical trials, investigator-sponsored studies, scientific communications, publications, clinical and scientific education, advisory boards, and congresses
  • Maintain the highest standards of scientific, clinical, and technical expertise in relevant therapeutic area(s)
  • 70% Travel required.
Desired Qualifications
  • Strong business acumen: has working knowledge of the multi-disciplinary functions involved in a company's drug development process, e.g. research, development, clinical operations, biostatistics, regulatory, commercial, etc.
  • Exemplifies the following core competencies: intellectual curiosity, managing change, teamwork and collaboration, communication, achieving results, decision-making, and clinical and scientific expertise.
  • Excellent project management skills: can prioritize multiple tasks and goals and ensure the timely, on-target, and within-budget accomplishment of such.
  • Proven effective interpersonal and communication skills.

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing stress, metabolism, and immune functions. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by excessive cortisol. Korlym was the first drug approved by the FDA for this condition in 2012. Corcept stands out from competitors by having discovered over 1,000 selective cortisol modulators and by heavily investing in research and development to create new treatments. The company's goal is to expand its product offerings while also providing educational resources to improve patient care and understanding of cortisol-related disorders.

Company Size

201-500

Company Stage

IPO

Total Funding

$39.7M

Headquarters

Menlo Park, California

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.
  • Advancements in drug delivery systems could enhance Corcept's product efficacy.
  • The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

What critics are saying

  • Teva's antitrust lawsuit could lead to legal expenses and market share loss.
  • Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.
  • Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

What makes Corcept Therapeutics unique

  • Corcept specializes in cortisol modulation, a niche with few direct competitors.
  • Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.
  • Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

2%

2 year growth

-3%
Investing.com
Dec 30th, 2024
Corcept files NDA for new Cushing's syndrome drug

Corcept introduced Korlym(R), the first FDA-approved treatment for Cushing's syndrome, in February 2012.

MarketBeat
Oct 8th, 2024
Algert Global LLC Invests $412,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Algert Global LLC invests $412,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT).

Defense World
Sep 29th, 2024
Evergreen Capital Management LLC Invests $217,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Evergreen Capital Management LLC invests $217,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT).

Defense World
Aug 16th, 2024
Cetera Advisors LLC Makes New Investment in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Cetera Advisors LLC makes new investment in Corcept Therapeutics Incorporated (NASDAQ:CORT).

Investing.com
Jun 29th, 2024
Teva study questions treatment breaks for migraine prevention

Teva has also initiated an antitrust lawsuit against Corcept Therapeutics (NASDAQ:CORT), alleging a monopoly over the Korlym market, a treatment for Cushing's syndrome.